Theravance Biopharma, Inc. (TBPH)

17.08 0.00 (0.00%) USD  |  NASDAQ  |  Sep 04, 16:00
17.08 0.00 (0.00%) After-Hours: 20:00
More

Theravance Biopharma SG&A Expense (TTM) : 76.09M for June 30, 2026

SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for TBPH.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical SG&A Expense (TTM) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 76.09M
March 31, 2026 77.89M
December 31, 2025 78.40M
September 30, 2025 75.94M
June 30, 2025 74.48M
March 31, 2025 73.11M
December 31, 2024 69.18M
September 30, 2024 66.16M
June 30, 2024 65.43M
March 31, 2024 67.65M
December 31, 2023 70.10M
September 30, 2023 71.34M
June 30, 2023 71.47M
March 31, 2023 68.42M
December 31, 2022 67.08M
September 30, 2022 71.86M
June 30, 2022 76.88M
March 31, 2022 86.59M
December 31, 2021 99.30M
September 30, 2021 107.84M
June 30, 2021 114.04M
March 31, 2021 112.89M
December 31, 2020 108.66M
September 30, 2020 111.65M
June 30, 2020 109.77M
Date Value
March 31, 2020 107.22M
December 31, 2019 106.08M
September 30, 2019 98.49M
June 30, 2019 94.76M
March 31, 2019 97.54M
December 31, 2018 97.06M
September 30, 2018 101.12M
June 30, 2018 100.18M
March 31, 2018 99.51M
December 31, 2017 95.59M
September 30, 2017 86.44M
June 30, 2017 85.78M
March 31, 2017 81.70M
December 31, 2016 84.51M
September 30, 2016 88.21M
June 30, 2016 90.77M
March 31, 2016 92.05M
December 31, 2015 90.20M
September 30, 2015 87.91M
June 30, 2015 82.77M
March 31, 2015 74.34M
December 31, 2014 71.65M
September 30, 2014 61.66M
June 30, 2014 52.76M
March 31, 2014 48.20M

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Zymeworks, Inc. 63.98M
Viatris, Inc. 3.981B
Ocular Therapeutix, Inc. 135.74M
ANI Pharmaceuticals, Inc. 324.76M
Corcept Therapeutics, Inc. 556.47M